Advancement in New Drug Discovery for Treatment of Hepatitis
The current existing treatments eliminates the virus in only a little more than half of all patients. Those drugs may also have unwanted side effects which makes it difficult for patients to take them. In recent years, tremendous research advances are transforming on treatment of Hepatitis. This progress has occurred in just last three years with new and effective therapies transforming the trajectory of the disease for many patients. The scientific advances that are made by biopharmaceutical researchers have already begun to have a tangible impact on thousands of patients. In all these areas, rapid progress is being made and more new medicines are on the way. The Food and Drug Administration has approved a new drug named Harvoni, which combines sofosbuvir and ledipasvir which cures Hepatitis C virus in just eight weeks.
Related Conference of Advancement in New Drug Discovery for Treatment of Hepatitis
15th International Conference on Pulmonary & Respiratory Medicine
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
16th International Conference on Chronic Obstructive Pulmonary Disease
Advancement in New Drug Discovery for Treatment of Hepatitis Conference Speakers
Recommended Sessions
- Advancement in New Drug Discovery for Treatment of Hepatitis
- Critical Care and Hepatology Nursing
- Epidemiology of Hepatitis
- Hepatitis Care
- Hepatocellular Carcinoma
- Intestinal Rehabilitation
- Liver Cancer
- Liver Diseases Diagnosis
- Liver Fibrosis
- Liver Transplantation and Surgery
- Molecular Biology of Hepatitis A, B, C, D and E Viruses
- Pancreatic Diseases
- Pathophysiology of Hepatitis
- Pediatric Gastroenterology, Hepatology and Nutrition
- Pregnancy and Liver Diseases
- Recent Advances in the Viral Hepatitis C Treatment
- Types of Hepatitis
- Viral Hepatitis Management
Related Journals
Are you interested in
- Asthma - Tuberculosis-2024 (France)
- Asthma and Allergy - COPD CONGRESS 2024 (UK)
- Asthma and COPD - COPD_2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - COPD CONGRESS 2024 (UK)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic bronchitis - COPD CONGRESS 2024 (UK)
- Chronic Obstructive Pulmonary Disease - COPD_2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- Co-Morbidities of COPD - COPD_2024 (France)
- COPD and Air Pollution - COPD CONGRESS 2024 (UK)
- COPD and Cardiovascular Diseases - COPD_2024 (France)
- COPD Complications - COPD_2024 (France)
- COPD Exacerbations - COPD_2024 (France)
- COPD Pathogenesis - COPD_2024 (France)
- COPD Pathogenesis - COPD CONGRESS 2024 (UK)
- COPD Therapeutics - COPD_2024 (France)
- COPD-Chronic obstructive pulmonary disease - COPD CONGRESS 2024 (UK)
- COPD: Sign and Symptoms - COPD_2024 (France)
- Depression and Anxiety in COPD - COPD CONGRESS 2024 (UK)
- Depression and anxiety in COPD - COPD_2024 (France)
- Diagnosis and Treatment of COPD - COPD CONGRESS 2024 (UK)
- Drug Discovery of COPD - COPD CONGRESS 2024 (UK)
- Drug Discovery of COPD - COPD_2024 (France)
- Effect of COVID-19 on Lungs - COPD CONGRESS 2024 (UK)
- Emphysema - COPD CONGRESS 2024 (UK)
- Epidemiology of COPD - COPD_2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Genetic risk factor of COPD - COPD_2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung cancer - COPD_2024 (France)
- Lung cancer - COPD CONGRESS 2024 (UK)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - COPD CONGRESS 2024 (UK)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - COPD CONGRESS 2024 (UK)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pathophysiology of COPD - COPD_2024 (France)
- Pediatric Neonatal Care in COPD - COPD CONGRESS 2024 (UK)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2024 (France)
- Pediatric Pulmonology & Critical care - COPD CONGRESS 2024 (UK)
- Prevention of COPD - COPD CONGRESS 2024 (UK)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary diseases - COPD CONGRESS 2024 (UK)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases-treatment and therapies - COPD_2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - COPD_2024 (France)
- Pulmonary Rehabilitation - COPD CONGRESS 2024 (UK)
- Respiratory and sleep Medicine - COPD CONGRESS 2024 (UK)
- Respiratory Failure and COPD Complications: - COPD CONGRESS 2024 (UK)
- Respiratory Tract Infections - COPD CONGRESS 2024 (UK)
- Self-Management and Prevention of COPD - COPD CONGRESS 2024 (UK)
- Self-Management and Prevention of COPD - COPD_2024 (France)
- Spirometry - COPD CONGRESS 2024 (UK)
- Stages & Severity on Lung Diseases - COPD CONGRESS 2024 (UK)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tobacco control - COPD CONGRESS 2024 (UK)
- Types of COPD - COPD_2024 (France)
- Types of COPD - COPD CONGRESS 2024 (UK)
- Zoonotic TB - Tuberculosis-2024 (France)